Vertex Announces it will Submit Cystic Fibrosis Medicines ORKAMBI® (lumacaftor/ivacaftor) as well as SYMKEVI® (tezacaftor/ivacaftor) to be Used in Combination with ivacaftor, to the Scottish Medicines Consortium for Appraisal
Vertex Pharmaceuticals (Europe) Limited today announced that, following constructive discussions with the Scottish Government, it will submit ORKAMBI® (lumacaftor/ivacaftor) as well as SYMKEVI® (tezacaftor/ivacaftor) to be used in combination with ivacaftor, to the Scottish Medicines Consortium (SMC) for appraisal. If accepted by the SMC for use on the NHS in Scotland, eligible patients with cystic fibrosis (CF) in Scotland could have access to these precision medicines in 2019.
“Our recent conversations with the Scottish Government, and the SMC’s orphan medicines process have provided important flexibility for evaluating precision medicines, such as cystic fibrosis transmembrane conductance regulator (CFTR) modulators. Their methods reflect the innovative nature of medicines that have the potential to extend life for patients with rare diseases, like CF,” said Ludovic Fenaux, Senior Vice President, Vertex International. “We are hopeful that, through this process, all eligible patients in Scotland could have access to our medicines soon.”
While the SMC reviews the submissions, clinicians could apply for access to lumacaftor/ivacaftor as well as tezacaftor/ivacaftor in combination with ivacaftor for individual patients based on clinical need via the Peer Approved Clinical System (PACS) Tier 2 process for ‘individual access to medicines not yet generally available on the NHS’. Vertex and the Scottish Government have also agreed to a confidential discount which will be applied to applications to the PACS Tier 2 process.
Approximately 900 people in Scotland live with CF.1 In the UK, the median age of death is 31 years.2 NHS Scotland estimates that one in 24 Scots have a CFTR mutation which, if carried by both parents, would lead to a child being born with CF.3
Should the appraisal be positive, patients in Scotland will join those in other countries around the world where all those eligible have access to lumacaftor/ivacaftor, including Austria, Australia, Denmark, Germany, the Republic of Ireland, Italy, the Netherlands, Sweden and the U.S.
About cystic fibrosis
Cystic fibrosis (CF) is a rare, life-shortening genetic disease affecting approximately 75,000 people in North America, Europe and Australia.4
CF is caused by a defective or missing cystic fibrosis transmembrane conductance regulator (CFTR) protein resulting from mutations in the CFTR gene. Children must inherit two defective CFTR genes — one from each parent — to have CF. There are approximately 2,000 known mutations in the CFTR gene.5 Some of these mutations, which can be determined by a genetic test, or genotyping test, lead to CF by creating non-working or too few CFTR proteins at the cell surface. The defective function or absence of CFTR protein results in poor flow of salt and water into and out of the cell in a number of organs. In the lungs, this leads to the build-up of abnormally thick, sticky mucus that can cause chronic lung infections and progressive lung damage in many patients that eventually leads to death.6
the F508del mutation
In people with two copies of the F508del mutation, the CFTR protein is not processed and trafficked normally within the cell, resulting in little-to-no CFTR protein at the cell surface. Patients with two copies of the F508del mutation are easily identified by a simple genetic test.
Lumacaftor/ivacaftor is a combination of lumacaftor, which is designed to increase the amount of mature protein at the cell surface by targeting the processing and trafficking defect of the F508del-CFTR protein, and ivacaftor, which is designed to enhance the function of the CFTR protein once it reaches the cell surface. Lumacaftor/ivacaftor is typically taken twice per day.
For complete product information, please see the Summary of Product Characteristics that can be found on www.ema.europa.eu.
combination with ivacaftor
Some mutations result in CFTR protein that is not processed or folded normally within the cell, and that generally does not reach the cell surface. Tezacaftor is designed to address the trafficking and processing defect of the CFTR protein to enable it to reach the cell surface and ivacaftor is designed to enhance the function of the CFTR protein once it reaches the cell surface.
For complete product information, please see the Summary of Product Characteristics that can be found on www.ema.europa.eu.
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases.
Founded in 1989 in Cambridge, Mass., Vertex's headquarters is now located in Boston's Innovation District. Today, the company has research and development sites and commercial offices in the United States, Europe, Canada, Australia and Latin America. Vertex is consistently recognized as one of the industry's top places to work, including being named to Science magazine's Top Employers in the life sciences ranking for nine years in a row. For additional information and the latest updates from the company, please visit www.vrtx.com.
Special Note Regarding Forward-looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, the statements in the first through third paragraphs of this press release. While Vertex believes the forward-looking statements contained in this press release are accurate, there are a number of factors that could cause actual events or results to differ materially from those indicated by such forward-looking statements. Those risks and uncertainties include, among other things, risks related to commercializing our products and the other risks listed under Risk Factors in Vertex's annual report and quarterly reports filed with the Securities and Exchange Commission. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available.
1 CF Registry Scotland Report 2015 Available at: https://www.cysticfibrosis.org.uk/the-work-we-do/uk-cf-registry/reporting-and-resources
(Accessed: December 2018)
2 UK Cystic Fibrosis Registry Annual Data Report 2016 Available at: https://www.cysticfibrosis.org.uk/~/media/documents/the-work-we-do/uk-cf-registry/uk-cf-registry-annual-data-report-2016.ashx?la=en (Accessed: December 2019)
3 National Services Scotland. Adult Cystic Fibrosis. Available at: http://www.nsd.scot.nhs.uk/services/specserv/adultcf.html (Accessed: December 2018)
4 Basharut A. S. et al. The cystic fibrosis drug market, Nature Reviews Drug Discovery vol.13, p. 721–722.2014 https://doi.org/10.1038/nrd4434
5 CF Trust. What are the causes of CF. Available at: https://www.cysticfibrosis.org.uk/what-is-cystic-fibrosis/what-causes-cystic-fibrosis (Accessed: December 2018)
6 Real-world outcomes in patients with cystic fibrosis treated with ivacaftor: 2016 US and UK cystic fibrosis Registry analyses.” Poster IPD2.02 during Session IPD2--What do We Learn from CFTR Modulator Use in Real Life. Poster IPD2.01 during Session IPD2. Poster presented at 41st European Cystic Fibrosis Conference, June 6-9, 2018, in Belgrade, Serbia
Vertex Pharmaceuticals Incorporated
Michael Partridge, +1-617-341-6108
Eric Rojas, +1-617-961-7205
Zach Barber, +1-617-341-6470 or
Sarah D'Souza, +1-617-341-6341
Europe & Australia:
Marie von Seyfried, +44-20-3204-527
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
DTCP Closes USD 350 Million Venture and Growth Fund Including Capital From Institutional and Corporate Investors25.6.2019 12:10:00 EEST | Tiedote
DTCP announced today that it has secured additional capital commitments from two corporate sponsors for its second Venture and Growth Fund: SK Telecom, the largest mobile operator in Korea and frontrunner in the fields of mobile network, AI, IoT, media and platform services, and ZEISS, an internationally leading technology enterprise operating in the fields of optics and optoelectronics, headquartered in Germany. The new investors join Deutsche Telekom, HarbourVest Partners, Neuberger Berman private equity fund sand others as Limited Partners (LPs) in the fund which boasts total commitments of USD 350 million and is now closed for further investors. The fund looks to deploy tickets between USD 5 and 50 million into Enterprise SaaS companies that: (i) operate in the sectors Cloud and Network Infrastructure, 5G/IoT, Digital Enterprise, Cybersecurity, Artificial Intelligence, and Marketing Technology; (ii) typically feature annualized recurring revenues of USD 5 million or more and (iii)
ClickFellas Chooses Digital Element to Increase Accuracy of IP Geotargeting Services25.6.2019 11:02:00 EEST | Tiedote
Digital Element, the global geolocation data and services provider, today announced that ClickFellas, a new advertising technology company, has chosen its NetAcuity EdgeTM technology to improve ad targeting for its clients. By incorporating Digital Element’s technology, ClickFellas is able to identify the consumer’s location, internet service provider, connection speed, mobile carrier, organisation name and proxy type without the user becoming personally identifiable. This highly accurate and granular IP data is used to facilitate standalone geotargeting and, when combined with additional factors such as gender, purchase intent and history data, allows Clickfellas to create tighter targeting profiles. Additionally, proxy data is used to help combat click fraud. “Digital Element’s technology helps us not only improve the accuracy of geotargeted advertising being served but also, ensures that we limit fraudulent traffic,” commented Franz Kanehl, Co-Founder ClickFellas Ltd. “For us, the b
iD Mobile Signs New MDS Global Contract to Take Advantage of Cloud-Based BSS Solution25.6.2019 11:00:00 EEST | Tiedote
MDS Global Ltd, a leading BSS-as-a-Service provider today announced that iD Mobile, one of the UK's largest mobile virtual network operators, has engaged in a new contract with the company, adopting MDS Global's CMP 8, a fully cloud-enabled Monetisation Platform designed to scale on-demand for new subscriber and business growth. Seeking greater flexibility to integrate social media and other self-serve and community applications, and to take advantage of the benefits of using Google's Cloud infrastructure, iD Mobile's move to MDS Global's CMP 8, the BSS-as-a-service platform that underpins the company's VNOnDemand solution, offers on-demand scalability for growth. Fully enabled for any public or private environment, iD Mobile can deploy new features and services within hours, keeping with the demands of today's feature-hungry consumers. The UK-based MVNO, offers customers an online and app-based portal giving them the freedom to tailor their iD Mobile package based on consumption requi
Tech Veteran Tej Kohli Calls for a Democratisation of AI25.6.2019 11:00:00 EEST | Tiedote
Tej Kohli, the London-based tech investor and entrepreneur, says that the hype around AI is still premature and that too much hype is creating a “bubble of enthusiasm” that risks causing disillusionment amongst the public when AI products do not start quickly improving their lives as promised. He says that AI will only be able to change the world when there is an accessible user interface which enables more entrepreneurs to build AI products that can enable all people to access the full benefits of the AI economy. This will require concerted international collaboration as well as major capital investment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190625005075/en/ Tej Kohli is a prominent investor in the global artificial intelligence economy (Photo: Business Wire) Kohli is ebullient about the prospects of AI to build a better world and has reiterated his belief that an exponential global AI economy could be worth $150 t
Banque du Caire, One of the Largest State-owned Banks in Egypt, Goes Live With Temenos to Redefine Digital Customer Experience25.6.2019 11:00:00 EEST | Tiedote
Temenos (SIX: TEMN), the banking software company, today announces that Banque du Caire has gone live with Temenos Infinity, the omni-channel digital banking product to transform the bank’s multiple banking channels into a fast, seamless and compelling customer journey. At this first stage of the Temenos Infinity implementation, the bank has gone live with digital channels servicing corporate and retail customers. The second phase of the implementation will deliver enhanced customer engagement with the Temenos Infinity real time marketing, digital engagement and digital analytics modules. Temenos Infinity will allow Banque du Caire, which currently operates a network of 225 branches, to increase product agility and take new products and services quicker to market. Temenos Infinity was implemented through APIs as an independent front office platform on the bank’s existing third party core banking system. The bank is also undergoing a core banking system overhaul after choosing the cloud
Eneco Holdings, Inc. to Spark Fuel Revolution with Low-Price, High-Concentration, Scalable Hydrogen-generation Technology25.6.2019 10:30:00 EEST | Tiedote
Eneco Holdings, Inc. is committed to the research and development of eco-friendly fuel technologies that reduce emissions of greenhouse gases. In 2015, we developed an emulsion fuel that achieves a complete fusion of 50% oil and 50% water. When used to drive buses on public roads, this fuel cuts carbon dioxide emissions roughly in half—the first achievement of its kind in Japan. This highly acclaimed technology is already installed and operating in Indonesia, Bangladesh, and the Philippines, and is set for introduction in Singapore, Australia, China, Laos, and Myanmar. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190625005393/en/ The Press Conference (Photo: Business Wire) Given the urgency of reducing greenhouse gas emissions worldwide, Eneco Holdings, Inc. has turned its attention to hydrogen gas in a bid to drive the transition to a zero-carbon economy. Although hydrogen fuel has already captured worldwide attention as
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme